Deutsche Bank
TOVX icon

Deutsche Bank’s Theriva Biologics TOVX Stock Holding History

Deutsche Bank’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17
Closed -$2K – 4819
2019
Q4 		$2K Buy
+17
New +$1.81K ﹤0.01% 4851
2018
Q2 		– Hold
0
– – – 5614
2018
Q1 		– Hold
0
– – – 5598
2017
Q4 		– Hold
0
– – – 5140
2017
Q3 		– Hold
0
– – – 5084
2017
Q2 		– Sell
-4
Closed -$19.9K – 5119
2017
Q1 		$20K Sell
4
-6
-60% -$41.9K ﹤0.01% 4507
2016
Q4 		$65K Buy
10
+9
+900% +$92.4K ﹤0.01% 4268
2016
Q3 		$21K Hold
1
– – ﹤0.01% 4526
2016
Q2 		$20K Sell
1
-4
-80% -$75.3K ﹤0.01% 4754
2016
Q1 		$110K Sell
5
-10
-67% -$150K ﹤0.01% 3956
2015
Q4 		$298K Buy
+15
New +$317K ﹤0.01% 3521
2015
Q3 		– Hold
0
– – – 5114
2013
Q4 		– Hold
0
– – – 5686
2013
Q3 		– Hold
0
– – – 5737

Other funds holding TOVX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank's TOVX Position: Q1 2020 in Review

Deutsche Bank sold out of Theriva Biologics (TOVX) in Q1 2020, closing a stake of 17 shares — an estimated $2K sold.

Deutsche Bank first reported a position in TOVX in Q4 2015 and held it in 7 quarters. The position peaked at $298K in Q4 2015. 18 funds tracked by Wall St. Rank hold TOVX as of Q1 2020.

  • Deutsche Bank reported no remaining Theriva Biologics position as of Q1 2020 after selling out during the quarter.
  • Deutsche Bank sold 17 Theriva Biologics shares in Q1 2020, an estimated $2K.
  • Deutsche Bank first reported a position in Theriva Biologics in Q4 2015 and held it in 7 quarters.
  • Deutsche Bank's Theriva Biologics position peaked at $298K in Q4 2015.
  • 18 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2020.

Based on Deutsche Bank's 13F filing for Q1 2020, filed 14 May 2020.